Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Men with metastatic hormone-refractory prostate cancer have a life expectancy of only about a year. More than 1000 such men were randomly assigned to receive the standard chemotherapy — mitoxantrone plus prednisone — or docetaxel (given every three weeks or every week) plus prednisone. Men who received docetaxel every 3 weeks survived for a median...
Alternative Titles
Full title
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_DiVA_org_uu_70011
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_70011
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa040720
